Compass Wealth Management LLC acquired a new position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 76,116 shares of the biotechnology company's stock, valued at approximately $541,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Sequoia Financial Advisors LLC lifted its position in shares of Grifols by 14.9% in the first quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company's stock worth $186,000 after purchasing an additional 3,399 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its stake in shares of Grifols by 66.5% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 60,063 shares of the biotechnology company's stock worth $427,000 after buying an additional 23,980 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its position in shares of Grifols by 20.3% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 266,005 shares of the biotechnology company's stock valued at $1,891,000 after acquiring an additional 44,818 shares during the last quarter. NBC Securities Inc. raised its holdings in Grifols by 112,543.1% during the first quarter. NBC Securities Inc. now owns 57,448 shares of the biotechnology company's stock worth $408,000 after acquiring an additional 57,397 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Grifols by 426.1% in the first quarter. GAMMA Investing LLC now owns 26,087 shares of the biotechnology company's stock valued at $1,850,000 after purchasing an additional 21,128 shares in the last quarter.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on GRFS shares. Wall Street Zen upgraded Grifols from a "buy" rating to a "strong-buy" rating in a report on Monday. JPMorgan Chase & Co. upped their price objective on shares of Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a report on Tuesday, June 17th.
View Our Latest Stock Report on GRFS
Grifols Price Performance
Shares of GRFS stock traded down $0.17 during trading on Monday, hitting $8.92. The company had a trading volume of 122,079 shares, compared to its average volume of 1,115,561. The stock's 50-day moving average price is $8.24 and its 200 day moving average price is $7.70. Grifols, S.A. has a one year low of $6.19 and a one year high of $9.96. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.97 and a current ratio of 2.60. The firm has a market capitalization of $6.13 billion, a P/E ratio of 7.62, a price-to-earnings-growth ratio of 0.33 and a beta of 0.55.
Grifols Profile
(
Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Further Reading

Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.